Neocure prevents 30,000 children from going blind each year due to ROP using AI technology. ROP can be treated, but it is often hard to find in time. Our AI analyzes the risk for each baby, helping to prevent missed diagnoses in hospitals where there aren't enough eye specialists. By helping doctors focus on the most urgent cases, we can stop blindness caused by ROP.
B-Lab is a biotechnology venture originating from Konan University, engaged in the production and sales of β-1,3-1,6-glucan nanoparticles and betaine-derived aqueous solutions. Based on biomimetic chemistry, these products drive the development of next-generation, safe, and environmentally harmonized biomaterial technologies applicable to the food, cosmetic, pharmaceutical, agricultural, and chemical industries.
L-glucose, a mirror isomer of D-glucose, is usually considered unusable by living organisms. However, in 2010, we discovered that malignant tumor cells specifically take up L-glucose (patented internationally). We have since worked with physicians and researchers to develop cancer-targeting drugs and diagnostics using L-glucose. Our goal is to bring a cure to patients with intractable cancers.
Development of small-molecule therapeutics targeting RNA.
A biotech startup developing T-cell and NK-cell therapies derived from low-immunogenicity iPS cells. It aims to provide new treatments for solid tumors and autoimmune diseases, contributing to the treatment of previously difficult-to-treat intractable diseases.
